Nifty
Sensex
:
:
9580.30
32424.10
90.20 (0.95%)
223.51 (0.69%)

Pharmaceuticals & Drugs

Rating :
52/99  (View)

BSE: 532305 | NSE: INDSWFTLAB

25.15
0.30 (1.21%)
29-May-2020 | 3:40PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  25.00
  •  25.90
  •  24.65
  •  24.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  16538
  •  4.16
  •  49.60
  •  15.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 150.67
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,268.92
  • N/A
  • 0.38

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 52.16%
  • 11.61%
  • 32.77%
  • FII
  • DII
  • Others
  • 0.46%
  • 0.00%
  • 3.00%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.27
  • 2.76
  • 2.75

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.65
  • 8.94
  • 5.15

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -3.76
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.64

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.57
  • 0.72
  • 0.81

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.37
  • 11.33
  • 9.93

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Net Sales
204
198
3%
192
167
15%
188
185
1%
194
0
0
Expenses
169
163
4%
164
136
21%
156
155
1%
160
0
0
EBITDA
35
35
-2%
27
31
-13%
32
30
4%
34
0
0
EBIDTM
17%
18%
14%
19%
17%
16%
18%
0%
Other Income
6
8
-22%
7
13
-51%
5
4
17%
12
0
0
Interest
27
22
22%
25
22
10%
28
5
474%
35
0
0
Depreciation
23
25
-11%
23
25
-12%
23
25
-11%
28
0
0
PBT
-9
40
-
-14
3
-
-14
28
-
-9
0
-
Tax
0
0
0
0
0
0
0
0
0
20
0
0
PAT
-9
40
-
-14
3
-
-14
28
-
-29
0
-
PATM
-4%
20%
-7%
2%
-7%
15%
-15%
0%
EPS
-1.90
8.46
-
-2.93
0.70
-
-2.91
5.91
-
-6.09
0.00
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
-
757
763
697
653
660
965
1,136
1,409
1,037
777
Net Sales Growth
-
-1%
9%
7%
-1%
-32%
-15%
-19%
36%
33%
 
Cost Of Goods Sold
-
398
391
392
353
407
755
912
1,123
773
570
Gross Profit
-
359
372
305
300
253
210
224
286
264
207
GP Margin
-
47%
49%
44%
46%
38%
22%
20%
20%
25%
27%
Total Expenditure
-
620
628
591
546
572
906
1,065
1,231
867
649
Power & Fuel Cost
-
37
30
26
23
35
37
32
12
16
15
% Of Sales
-
5%
4%
4%
3%
5%
4%
3%
1%
2%
2%
Employee Cost
-
90
88
70
63
51
45
41
29
20
20
% Of Sales
-
12%
12%
10%
10%
8%
5%
4%
2%
2%
3%
Manufacturing Exp.
-
46
64
43
39
30
26
29
28
21
18
% Of Sales
-
6%
8%
6%
6%
5%
3%
3%
2%
2%
2%
General & Admin Exp.
-
28
29
23
22
20
22
21
18
17
11
% Of Sales
-
4%
4%
3%
3%
3%
2%
2%
1%
2%
1%
Selling & Distn. Exp.
-
21
28
29
29
28
14
24
18
16
15
% Of Sales
-
3%
4%
4%
4%
4%
1%
2%
1%
2%
2%
Miscellaneous Exp.
-
0
0
8
19
0
7
6
2
4
15
% Of Sales
-
0%
0%
1%
3%
0%
1%
1%
0%
0%
0%
EBITDA
-
136
134
106
107
89
59
72
178
170
128
EBITDA Margin
-
18%
18%
15%
16%
13%
6%
6%
13%
16%
16%
Other Income
-
36
26
23
16
22
14
18
34
11
15
Interest
-
92
35
90
106
117
117
140
85
57
51
Depreciation
-
104
87
88
85
84
66
54
40
39
42
PBT
-
-24
38
-50
-68
-91
-109
-105
87
86
50
Tax
-
21
14
-16
-24
-24
-20
-1
-3
0
-3
Tax Rate
-
35%
39%
29%
29%
17%
14%
1%
-3%
-1%
-6%
PAT
-
38
22
-39
-59
-119
-122
-118
89
89
56
PAT before Minority Interest
-
38
22
-39
-59
-119
-122
-118
89
89
56
Minority Interest
-
0
0
0
0
0
0
0
0
0
0
PAT Margin
-
5%
3%
-6%
-9%
-18%
-13%
-10%
6%
9%
7%
PAT Growth
-
75%
156%
33%
51%
2%
-3%
-232%
0%
59%
 
EPS
-
8.08
4.62
-8.22
-12.33
-25.08
-25.63
-24.77
18.73
18.79
11.85

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
604
553
531
517
595
725
853
824
578
448
Share Capital
48
46
45
42
42
41
39
38
34
28
Total Reserves
556
506
483
476
553
675
805
783
533
416
Non-Current Liabilities
901
438
495
717
811
983
859
777
660
632
Secured Loans
954
504
564
667
723
862
757
662
556
480
Unsecured Loans
12
17
28
79
93
102
63
50
44
108
Long Term Provisions
14
13
9
0
0
0
0
0
0
0
Current Liabilities
331
936
1,005
951
833
630
663
618
495
194
Trade Payables
127
129
102
132
134
214
203
254
235
167
Other Current Liabilities
106
490
497
315
249
22
25
45
18
13
Short Term Borrowings
93
311
406
504
450
391
422
302
220
0
Short Term Provisions
6
6
0
0
0
4
13
18
22
14
Total Liabilities
1,836
1,927
2,031
2,185
2,239
2,339
2,376
2,219
1,733
1,274
Net Block
903
925
1,033
1,099
1,117
1,174
1,171
910
547
481
Gross Block
1,380
1,349
1,407
1,421
1,404
1,405
1,351
1,042
704
598
Accumulated Depreciation
478
425
374
322
287
232
181
132
157
116
Non Current Assets
1,011
1,088
1,202
1,264
1,319
1,350
1,351
1,223
883
672
Capital Work in Progress
20
69
70
78
113
78
161
294
315
173
Non Current Investment
31
31
31
18
18
17
17
17
18
18
Long Term Loans & Adv.
57
64
54
69
72
81
2
2
2
0
Other Non Current Assets
0
0
14
0
0
0
0
0
0
0
Current Assets
825
839
829
922
920
989
1,025
997
851
603
Current Investments
0
0
0
0
0
0
0
2
30
45
Inventories
329
317
344
356
348
377
451
494
366
237
Sundry Debtors
351
408
357
372
389
444
413
304
294
180
Cash & Bank
30
9
16
23
20
21
18
47
54
54
Other Current Assets
115
13
16
13
163
147
143
150
107
86
Short Term Loans & Adv.
93
92
95
157
144
126
115
122
79
86
Net Current Assets
494
-97
-176
-29
87
359
362
379
355
409
Total Assets
1,836
1,927
2,031
2,185
2,239
2,339
2,376
2,219
1,733
1,274

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
-64
73
96
79
98
66
-47
73
18
44
PBT
-24
38
-50
-68
-91
-109
-105
87
86
50
Adjustment
186
104
168
186
170
145
112
57
61
59
Changes in Working Capital
-224
-68
-22
-39
23
40
-53
-53
-117
-60
Cash after chg. in Working capital
-62
73
96
79
102
75
-47
90
30
49
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-3
0
0
0
-4
-9
0
-17
-13
-5
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-13
-17
-31
-30
-36
-27
-48
-204
-231
-192
Net Fixed Assets
17
59
22
18
-35
29
-176
-316
-249
-150
Net Investments
0
0
-13
0
1
0
2
29
10
-45
Others
-30
-77
-40
-48
-2
-57
126
84
8
2
Cash from Financing Activity
100
-62
-69
-48
-64
-38
66
125
214
179
Net Cash Inflow / Outflow
23
-6
-4
2
-1
0
-29
-6
0
31
Opening Cash & Equivalents
9
16
23
20
21
18
47
54
54
23
Closing Cash & Equivalent
30
9
16
22
20
21
18
47
54
54

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
77
66
58
57
67
93
126
158
141
127
ROA
2%
1%
-2%
-3%
-5%
-5%
-5%
5%
6%
5%
ROE
12%
8%
-16%
-23%
-36%
-28%
-22%
16%
21%
18%
ROCE
10%
5%
2%
1%
-2%
-1%
1%
12%
13%
13%
Fixed Asset Turnover
0.56
0.56
0.51
0.48
0.48
0.71
0.96
1.63
1.61
1.34
Receivable days
182
181
186
206
223
159
113
77
83
68
Inventory Days
155
156
178
191
194
154
150
110
105
103
Payable days
65
61
64
13
30
81
76
69
80
86
Cash Conversion Cycle
272
277
300
385
388
232
187
117
108
85
Total Debt/Equity
3.15
4.38
4.77
6.25
5.12
3.56
2.51
1.69
1.70
1.67
Interest Cover
2
2
0
0
0
0
0
2
3
2

News Update


  • Ind-Swift Laboratories receives EIR from USFDA for API facility in Punjab
    12th May 2020, 09:05 AM

    The USFDA inspection was conducted from March 9, 2020 to March 13, 2020

    Read More
  • USFDA completes inspection at Ind Swift Laboratories’ API facility in Punjab
    16th Mar 2020, 09:16 AM

    The USFDA has cleared this inspection without any 483 observation

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.